A Medical Device Daily
A merger agreement between Cytta and Opthalmic International (OI; both Fountain Hills, Arizona) has been cancelled. G. R. Smith, CEO of Cytta, said that all stock given to OI would be returned to Cytta and all of OI's assets removed. Upon completion of this transaction, Smith said he intends to resign his position with Cytta and reinstate previous officers.
OI is developing PNeumatic Trabeculoplasty (PNT). According to the company, PNT is a safe, noninvasive method clinically demonstrated to lower elevated intraocular pressure in patients with primary open angle glaucoma, pigmentary glaucoma or ocular hypertension. The technology is approved in Canada and the European Economic Community, according to OI.
PNT uses a specially designed, sterile, disposable PNT suction ring. The PNT ring is applied to the patient's eye and connected to a vacuum controller which has been specifically designed to delivery a vacuum of about 21 inches of Hg for a duration of one minute, the company said. A PNT treatment involves two applications with a rest period of five minutes between each. The treatment is repeated after one week and then on average, every three months unless a physician determines otherwise. According to the company, PNT appears to act on the trabecular meshwork resulting in an increase in the facility of aqueous outflow.